Schedule Update - effective 1 September 2011 (text extract)

This is the text extract for Schedule Update - effective 1 September 2011, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 September 2011

Section H cumulative for August and September 2011

Contents

Summary of PHARMAC decisions effective 1 September 2011 ...................... 3 Legislation changes impact on the Pharmaceutical Schedule ........................ 5 Candesartan – new brand listed .................................................................... 5 Zyprexa and Zyprexa Zydis brands of olanzapine – removal of Special Authorities and subsidy reduction ................................... 6 Omezol Relief capsules .................................................................................. 6 Budesonide 3 mg capsules – wider access ..................................................... 7 Litak injection delist now revoked ................................................................. 7 Ensure powder 400 g pack size discontinuation ........................................... 7 Diabetes Nurse Prescribers’ prescriptions ...................................................... 8 News in Brief ................................................................................................. 8 Named Specialist for antiretrovirals............................................................... 9 Tender News ................................................................................................ 10 Looking Forward ......................................................................................... 13 Sole Subsidised Supply products cumulative to September 2011................ 14 New Listings ................................................................................................ 21 Changes to Restrictions ............................................................................... 22 Changes to Subsidy and Manufacturer’s Price............................................. 34 Changes to General Rules............................................................................ 37 Changes to Brand Name ............................................................................. 38 Changes to Sole Subsidised Supply ............................................................. 39 Delisted Items ............................................................................................. 40 Items to be Delisted .................................................................................... 41 Section H changes to Part II ........................................................................ 42 Section H changes to Part III........................................................................ 47 Section H changes to General Rules ............................................................ 48 Index ........................................................................................................... 50

Summary of PharmaC decisions

effeCtIve 1 SePtemBer 2011 New listings (page 21) • Pravastatin (Cholvastin) tab 20 mg and 40 mg – Special Authority – Retail pharmacy • Candesartan (Candestar) tab 4 mg, 8 mg, 16 mg and 32 mg – Special Authority – Retail pharmacy – maximum daily doses apply • Finasteride (Rex Medical) tab 5 mg – Special Authority – Retail pharmacy • Levothyroxine (Synthroid) tab 100 μg, 90 tab pack • Terbinafine (Dr Reddy’s Terbinafine) tab 250 mg • Mefenamic acid (Ponstan) cap 250 mg, 50 cap pack – additional subsidy by Special Authority – Retail pharmacy • Bicalutamide (Bicalaccord) tab 50 mg – Special Authority – Retail pharmacy Changes to restrictions (pages 22-33) • Budesonide (Entocort CIR) cap 3 mg – amended Special Authority criteria • Benzylpenicillin sodium (Penicillin G) inj 600 mg – amended presentation description • Adalimumab inj 40 mg per 0.8 ml prefilled pen and syringe (HumiraPen and Humira) – amended Special Authority criteria • Etanercept (Enbrel) inj 25 mg, and 50 mg autoinjector and prefilled syringe – amended Special Authority criteria • Olanzapine (Zyprexa) tab 2.5 mg, 5 mg and 10 mg – Special Authority removed • Olanzapine (Zyprexa Zydis) wafer 5 mg and 10 mg – Special Authority removed • Thalidomide cap 50 mg (Thalidomide Pharmion and Thalomid) and cap 100 mg (Thalomid) – removal of only on a controlled drug form Increased subsidy (pages 34-36) • Hyoscine n-butylbromide (Buscopan) inj 20 mg, 1 ml • Zinc sulphate (Zincaps) cap 137.4 mg (50 mg elemental) • Clotrimazole (Clomazol) crm 1%, 20 g OP • Miconazole nitrate (Multichem) crm 2%, 15 g OP • Hydrocortisone (Pharmacy Health) crm 1%, 500 g • Hydrocortisone (ABM) powder, 25 g • Tar with triethanolamine lauryl sulphate and fluorescein (Pinetarsol) soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium, 500 ml and 1,000 ml • Ergometrine maleate (DBL Ergometrine) inj 500 μg per ml, 1 ml • Norethisterone (Primolut N) tab 5 mg

Summary of PharmaC decisions – effective 1 September 2011 (continued) • Mebendazole (De-Worm) tab 100 mg • Amoxycillin (Ibiamox) inj 250 mg, 500 mg and 1 g • Benzylpenicillin sodium (penicillin G) (Sandoz) inj 600 mg • Flucloxacillin sodium (Flucloxin) inj 250 mg, 500 mg and 1 g • Procaine penicillin (Cilicaine) inj 1.5 mega u • Morphine sulphate (DBL Morphine Sulphate) inj 5 mg per ml, 1 ml; 10 mg per ml, 1 ml; 15 mg per ml, 1 ml; and 30 mg per ml, 1 ml • Pethidine hydrochloride (DBL Pethidine Hydrochloride) inj 50 mg per ml, 1 ml and 2 ml • Lithium carbonate (Douglas) cap 250 mg • Temazepam (Normison) tab 10 mg • Cyclophosphamide (Endoxan) inj 1 g and 2 g • Calcium folinate (DBL Leucovorin Calcium) tab 15 mg • Cetirizine hydrochloride (Cetirizine – AFT) oral liq 1 mg per ml • Aminophylline (DBL Aminophylline) inj 25 mg per ml, 10 ml • Acetazolamide (Diamox) tab 250 mg • Carbohydrate supplement (Polycal) powder Decreased subsidy (pages 34-36) • Calcium carbonate (Calsource) tab eff 1.75 g (1 g elemental) • Imiquimod (Aldara) crm 5% • Olanzapine (Zyprexa) tab 2.5 mg, 5 mg and 10 mg • Olanzapine (Zyprexa Zydis) wafer 5 mg and 10 mg • Fludarabine phosphate (Baxter) inj 50 mg for ECP

Pharmaceutical Schedule - Update News

Legislation changes impact on the Pharmaceutical Schedule

The Medicines Amendment Regulations 2011 and the Misuse of Drugs Amendment Act 2011 recently became law which resulted in the following changes to the Pharmaceutical Schedule. Brand substitution Pharmacists may now substitute an alternative brand of a prescribed medicine provided: • There are no clinical reasons why the substitution should not occur • The prescriber has not marked the prescription with a statement such as “no brand substitution permitted”, and • The pharmacist records details of the brand substitution on the prescription and informs the patient of the change of brand. The Pharmaceutical Schedule rule 4.6 has

been amended accordingly. Please see page 37 for information. Thalidomide reclassification Thalidomide has been reclassified as a prescription medicine. Prescriptions for thalidomide should now be on a standard prescription form and no longer need to be prescribed on the triplicate controlled drug prescription form. The subsidy for thalidomide remains unchanged.

Candesartan – new brand listed

A new brand of candesartan will be subsidised from 1 September 2011. Candestar 4 mg, 8 mg, 16 mg and 32 mg tablets will be subsidised subject to the same Special Authority and maximum daily dose restrictions as the Atacand brand of candesartan. The Atacand brand will continue to be listed in Section B of the Pharmaceutical Schedule subject to its current subsidy and current restrictions.

Pharmaceutical Schedule - Update News

Zyprexa and Zyprexa Zydis brands of olanzapine – removal of Special Authorities and subsidy reduction

The Special Authority for subsidy for the Zyprexa brand of olanzapine tablets and the Zyprexa Zydis brand of olanzapine wafers will be removed from 1 September 2011. This will mean that all brands of olanzapine listed in the Pharmaceutical Schedule will be able to be accessed without a Special Authority for subsidy. The subsidy for all strengths of Zyprexa tablets and Zyprexa Zydis wafers will be reduced from 1 September 2011 to the same level as the other funded brands of olanzapine. Please note that Eli Lilly has advised that it will not be decreasing the price of Zyprexa and Zyprexa Zydis, so dispensings of these brands will incur a manufacturer’s surcharge from 1 September 2011.

Omezol Relief capsules

There have been some enquiries with regard to dispensing Omezol Relief (omeprazole) capsules which require breaking of an original 90 capsule pack. The advice received from Mylan New Zealand Ltd is as follows: Dispensing into quantities less than 90 capsules — Dispense capsules into bottles similar to those provided by Mylan and include one of the desiccants from the original pack. It is recommended patients do not store the dispensed capsules for longer than the prescription period. Advise patients that the capsules should be kept in the dispensed bottle, whether in Mylan’s original container or the container used by the pharmacy, with the lid tightly closed until it is time to take them. The capsules should be stored in a cool, dry place and not in the bathroom or kitchen.

Pharmaceutical Schedule - Update News

Budesonide 3 mg capsules – wider access

The Special Authority that applies to budesonide 3 mg capsules (Entocort CIR) will be amended from 1 September 2011. Budesonide 3 mg capsules will be funded for patients with microscopic colitis, patients with Crohn’s disease who have psychiatric problems or with relapse during pregnancy, and patients with Gut Graft vs Host disease (GVHD). The Special Authority approval period has also been lengthened from 3 to 6 months. The restriction that permitted patients to have only 1 prior approval in the last year will be removed from 1 September 2011.

Litak injection delist now revoked

Litak (cladribine) 2 mg per ml, 5 ml injection was to be delisted from the Pharmaceutical Schedule from 1 September 2011. This decision has now been revoked to cover an out-of-stock on Leustatin injection 1 mg per ml, 10 ml. Litak will continue to be subsidised under its current subsidy restrictions of PCT only – Specialist. Litak is an unapproved medicine in New Zealand and is supplied under Section 29 of the Medicines Act 1981.

Ensure powder 400 g pack size discontinuation

Abbott Nutrition has notified the discontinuation of all flavours of the 400 g pack size of Ensure powder. Ensure powder 900 g pack size in chocolate and vanilla will remain available and subsidised. The 400 g pack size will be delisted from the Pharmaceutical Schedule from 1 March 2012. Ensure Plus 237 ml can, coffee latte flavour, has also been discontinued by Abbott Nutrition and will be delisted from the Pharmaceutical Schedule from 1 March 2012.

Pharmaceutical Schedule - Update News

Diabetes Nurse Prescribers’ prescriptions

The demonstration site project for diabetes nurse prescribing moves into its evaluation phase after September 2011. However, the twelve named Diabetes Nurse Prescribers will continue to be able to prescribe after September and have their prescriptions subsidised. They will continue to prescribe under the collaborative framework with Diabetes Specialists. The current list of medicines they are able to prescribe will not change. We will publish further information on the result of the evaluation as it comes to hand.

News in Brief

• Synthroid (levothyroxine) 100 µg tablets will be supplied in a 90 tablet pack size from 1 September 2011. The 1,000 tablet pack size will be delisted from 1 March 2012. Pack sizes for the remaining strengths of Synthroid will also change over the coming months. • The listing date of Mylan New Zealand Ltd’s ciprofloxacin 250 mg, 500 mg and 750 mg tablets, Cipflox, has been delayed from 1 September 2011 until 1 October 2011. All strengths of Rex Medical’s ciprofloxacin tablets will continue to be listed and fully subsidised until 1 December 2011 when they will be reference priced to Cipflox. Rex Medical’s ciprofloxacin tablets will now be delisted on 1 March 2012. • Dr Reddy’s brand of terbinafine 250 mg tablets will be subsidised from 1 September 2011 and will now be subsidised in a 14 tablet pack, at a price and subsidy of $1.78 per pack. PHARMAC has previously notified that this brand would be subsidised in a 28 tablet pack. • Mylan New Zealand Ltd’s cefuroxime sodium 1.5 g injection will now be listed in Part II of Section H of the Pharmaceutical Schedule from 1 February 2012. This had previously been incorrectly notified as 1 January 2012. Zinacef 1.5 g injection will now be delisted from Part II of Section H of the Pharmaceutical Schedule on 1 April 2012. In addition, Mylan’s cefuroxime sodium 1.5 g injection will be listed in Section B of the Pharmaceutical Schedule from 1 February 2012 at a price and subsidy of $2.65 per injection. • Due to a delay in the production of stock for the New Zealand market, the listing of all strengths of pramipexole hydrochloride (Dr Reddy’s pramipexole) tablets will be delayed from 1 September 2011 until further notice.

Pharmaceutical Schedule - Update News

Named Specialist for antiretrovirals

Below is a list of currently approved named Specialists that the Ministry of Health has approved to prescribe HIV antiretroviral agents in New Zealand Auckland Dr Sunita Azariah Dr Emma Best Dr Simon Briggs Dr Rod Ellis-Pegler Dr Rick Franklin Dr Rupert Handy Dr Jacqueline Hilton Dr David Holland Dr Joan Ingram Prof. Diana Lennon Dr Mitzi Nisbet Dr Nicky Perkins Dr Murray Reid Dr Stephen Ritchie Dr Sally Roberts Dr Simon Rowley Dr Mark Thomas Dr Leslie Voss Dr Liz Wilson Hamilton Dr Graham Mills Dr Jane Morgan Tauranga Dr Massimo Giola Dr Katherine Grimwade Napier Dr Andrew Burns Dr Richard Meech Palmerston North Dr Anne Robertson Wellington Dr Tim Blackmore Dr Nigel Raymond Dr Richard Steele Nelson Dr Richard Everts Christchurch Dr Stephen Chambers Dr Sarah Metcalf Dr Alan Pithie Dr Tony Walls Dunedin Dr Geoffery Clover Dr Igor Melnychuk

tender News

Sole Subsidised Supply changes – effective 1 October 2011

Chemical Name Amantadine hydrochloride Aqueous cream Bendrofluazide Bendrofluazide Betaxolol hydrochloride Betaxolol hydrochloride Calcitonin Cetirizine hydrochloride Chlorhexidine gluconate Citalopram hyrobromide Compound electrolytes Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone Dexamethasone with neomycin and polymyxin b sulphate Dexamethasone with neomycin and polymyxin b sulphate Dextrose Diclofenac sodium Diclofenac sodium Diclofenac sodium Diclofenac sodium Diclofenac sodium Diclofenac sodium Docusate sodium Docusate sodium Doxycycline hydrochloride Emulsifying ointment Fentanyl citrate Fentanyl citrate Gliclazide Presentation; Pack size Cap 100 mg; 60 cap Crm; 500 g Tab 2.5 mg; 500 tab Tab 5 mg; 500 tab Eye drops 0.5%; 5 ml OP Eye drops 0.25%; 5 ml OP Inj 100 iu per ml, 1 ml; 5 inj Tab 10 mg; 100 tab Soln 4%; 500 ml Tab 20 mg; 84 tab Powder for soln for oral use 4.4 g; 5 sach Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs; 84 tab Nasal spray 10 µg per dose; 6 ml OP Eye oint 0.1%; 3.5 g OP Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g; 3.5 g OP Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g; 5 ml OP Inj 50%, 10 ml; 5 inj Inj 25 mg per ml, 3 ml; 5 inj Eye drops 1 mg per ml; 5 ml Suppos 12.5 mg; 10 supp Suppos 25 mg; 10 supp Suppos 50 mg; 10 supp Suppos 100 mg; 10 supp Cap 50 mg; 100 cap Cap 120 mg; 100 cap Tab 100 mg; 250 tab Oint BP; 500 g Inj 50 µg per ml, 2 ml; 10 inj Inj 50 µg per ml, 10 ml; 10 inj Tab 80 mg; 500 tab Sole Subsidised Supply brand (and supplier) Symmetrel (Novartis) AFT (AFT) Arrow-Bendrofluazide (Arrow) Arrow-Bendrofluazide (Arrow) Betoptic (Pharmaco) Betoptic S (Pharmaco) Miacalcic (Novartis) Zetop (Arrow) Orion (Orion) Arrow-Citalopram (Arrow) Electral (Arrow) Ginet 84 (Rex Medical) Desmopressin-PH&T (AFT) Maxidex (Alcon) Maxitrol (Alcon) Maxitrol (Alcon) Biomed (Biomed) Voltaren (Novartis) Voltaren Ophtha (Novartis) Voltaren (Novartis) Voltaren (Novartis) Voltaren (Novartis) Voltaren (Novartis) Laxofast 50 (Arrow) Laxofast 120 (Arrow) Doxine (Mylan) AFT (AFT) Boucher and Muir (Goldshield) Boucher and Muir (Goldshield) Apo-Gliclazide (Apotex)

Sole Subsidised Supply changes effective 1 October 2011 (continued)

Chemical Name Glyceryl trinitrate Glyceryl trinitrate Glyceryl trinitrate Hydrocortisone with wool fat and mineral oil Hyoscine N-butylbromide Ketoconazole Lignocaine hydrochloride Lodoxamide trometamol Mebeverine hydrochloride Mesalazine Metoclopramide hydrochloride Naphazoline hydrochloride Neostigmine Nicotine Nicotine Nicotine Nicotine Nicotine Nicotine Nicotinic acid Nicotinic acid Norfloxacin Nystatin Omeprazole Omeprazole Pantoprazole Paracetamol Pergolide Pergolide Presentation; Pack size TDDS 5 mg; 30 patch TDDS 10 mg; 30 patch Tab 600 µg; 100 tab Lotn 1% with wool fat hydrous 3% and mineral oil; 250 ml Tab 10 mg; 20 tab Shampoo 2%; 100 ml OP Viscous soln 2%; 200 ml OP Eye drops 0.1%; 10 ml OP Tab 135 mg; 90 tab Suppos 500 mg; 20 supp Inj 5 mg per ml, 2 ml; 10 inj Eye drops 0.1%; 15 ml OP Inj 2.5 mg per ml, 1 ml; 50 inj Gum 2 mg (Mint); 384 piece Gum 2 mg (Classic); 384 piece Gum 2 mg (Fruit); 384 piece Gum 4 mg (Mint); 384 piece Gum 4 mg (Classic); 384 piece Gum 4 mg (Fruit); 384 piece Tab 50 mg; 100 tab Tab 500 mg; 100 tab Tab 400 mg; 100 tab Oral liq 100,000 u per ml; 24 ml OP Powder; 5 g Inj 40 mg; 5 inj Inj 40 mg; 1 inj Oral liq 250 mg per 5 ml; 1000 ml Tab 0.25 mg; 100 tab Tab 1 mg; 100 tab Sole Subsidised Supply brand (and supplier) Nitroderm TTS (Novartis Consumer) Nitroderm TTS (Novartis Consumer) Lycinate (Aspen) DP Lotn HC (Douglas) Gastrosoothe (AFT) Sebizole (Douglas) Xylocaine Viscous (AstraZeneca) Lomide (Alcon) Colofac (Solvay) Asacol (Baxter) Pfizer (Pfizer) Naphcon Forte (Pharmaco) AstraZeneca (Astra) Habitrol (Novartis Consumer) Habitrol (Novartis Consumer) Habitrol (Novartis Consumer) Habitrol (Novartis Consumer) Habitrol (Novartis Consumer) Habitrol (Novartis Consumer) Apo-Nicotinic Acid (Apotex) Apo-Nicotinic Acid (Apotex) Arrow-Norfloxacin (Arrow) Nilstat (Aspen) Midwest (MidWest) Dr Reddy's Omeprazole (Dr Reddy's) Pantocid IV (API) Paracare Double Strength (API) Permax (Aspen) Permax (Aspen)

Sole Subsidised Supply changes effective 1 October 2011 (continued)

Chemical Name Permethrin Permethrin Poloxamer Pyridostigmine bromide Pyridostigmine bromide Pyridoxine hydrochloride Pyridoxine hydrochloride Ranitidine hydrochloride Ranitidine hydrochloride Ranitidine hydrochloride Simvastatin Simvastatin Simvastatin Simvastatin Tetracosactrin Tetracosactrin Tobramycin Tobramycin Tobramycin Tolcapone Tramadol hydrochloride Triamcinolone acetonide Triamcinolone acetonide Triamcinolone acetonide Tropicamide Tropicamide Tyloxapol Vancomycin hydrochloride Verapamil hydrochloride Verapamil hydrochloride Zopiclone Presentation; Pack size Crm 5%; 30 g OP Lotn 5%; 30 ml OP Oral drops 10%; 30 ml OP Tab 60 mg; 100 tab Tab 60 mg; 200 tab Tab 25 mg; 90 tab Tab 50 mg; 100 tab Oral liq 150 mg per 10 ml; 300 ml Tab 150 mg; 250 tab Tab 300 mg; 250 tab Tab 10 mg; 90 tab Tab 20 mg; 90 tab Tab 40 mg; 90 tab Tab 80 mg; 90 tab Inj 250 µg; 10 inj Inj 1 mg per ml 1 ml; 1 inj Eye oint 0.3%; 3.5 g OP Inj 40 mg per ml, 2 ml; 5 inj Eye drops 0.3%; 5 ml OP Tab 100 mg; 100 tab Cap 50 mg; 100 cap Crm 0.02%; 100 g OP Oint 0.02%; 100 g OP 0.1% in Dental Paste USP; 5 g OP Eye drops 1%; 15 ml OP Eye drops 0.5%; 15 ml OP Eye drops 0.25%; 15 ml OP Inj 500 mg; 1 inj Tab 40 mg; 100 tab Tab 80 mg; 100 tab Tab 7.5 mg; 500 tab Sole Subsidised Supply brand (and supplier) Lyderm (API) A-Scabies (AFT) Coloxyl (Aspen) Mestinon (Mylan) Mestinon (Mylan) PyridoxADE (Goldshield) Apo-Pyridoxine (Apotex) Peptisoothe (AFT) Arrow-Ranitidine (Arrow) Arrow-Ranitidine (Arrow) Arrow-Simva 10mg (Arrow) Arrow-Simva 20mg (Arrow) Arrow-Simva 40mg (Arrow) Arrow-Simva 80mg (Arrow) Synacthen (Novartis) Synacthen Depot (Novartis) Tobrex (Alcon) DBL Tobramycin (Hospira) Tobrex (Alcon) Tasmar (Valeant) Arrow-Tramadol (Arrow) Aristocort (Aspen) Aristocort (Aspen) Oracort (AFT) Mydriacyl (Alcon) Mydriacyl (Alcon) Enuclene (Alcon) Mylan (Mylan) Isoptin (Abbott) Isoptin (Abbott) Apo-Zopiclone (Apotex)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for implementation 1 October 2011 • Acitretin (Novatretin) cap 10 mg and 25 mg – new listing with existing Special Authority • Budesonide (Budenocort) powder for inhalation 200 μg per dose and 400 μg per dose – subsidy decrease • Losartan (Lostaar) tab 12.5 mg, 25 mg, 50 mg and 100 mg – new listing with existing Special Authority • Losartan (Arrow Losartan & Hydrochlorothiazide) tab 50 mg with hydrochlorothiazine 12.5 mg – new listing with existing Special Authority • Sunitinib (Sutent) cap 12.5 mg, 25 mg and 50 mg – amended Special Authority criteria • Trastuzumab inj 150 mg vial and 440 mg vial (Herceptin), and inj 1 mg for ECP (Baxter) – amended Special Authority criteria

Sole Subsidised Supply Products – cumulative to September 2011

Generic Name

Abacabir sulphate Acarbose Aciclovir Amitriptyline Amoxycillin Amoxycillin clavulanate

Presentation

Oral liq 20 mg per ml Tab 300 mg Tab 50 mg & 100 mg Tab dispersible 200 mg, 400 mg & 800 mg Tab 25 mg & 50 mg Cap 250 mg & 500 mg Grans for oral liq 250 mg per 5 ml Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab 100 mg Tab 100 mg Tab dispersible 300 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Tab 50 mg Inj 50 mg Tab 500 mg Tab 10 mg Scalp app 0.1% Tab 5 mg Crm, aqueous, BP Lotn, BP Cap 0.25 µg & 0.5 µg Tab 12.5 mg, 25 mg & 50 mg Oral liq 5 mg per ml Grans for oral liq 125 mg per 5 ml Inj 500 mg Inj 1 g Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Crm BP Eye drops 0.5% Eye oint 1% Handrub 1% with ethanol 70% Nail soln 8% Tab 0.5 mg, 2.5 mg & 5 mg

Brand Name Expiry Date*

Ziagen Ziagen Glucobay Lovir Amitrip Alphamox Ospamox Curam Curam 2014 2012 2013 2014 2013 2012 2012

Ascorbic acid Aspirin Atenolol Atropine sulphate Azathioprine Azithromycin Baclofen Betamethasone valerate Bisacodyl Calamine Calcitriol Captopril Cefaclor monohydrate Ceftriaxone sodium Cephalexin monohydrate Cetomacrogol Chloramphenicol Chlorhexidine gluconate Ciclopiroxolamine Cilazapril

Vitala-C Ethics Aspirin EC Ethics Aspirin Atenolol Tablet USP AstraZeneca Imuprine Imuran Arrow-Azithromycin Pacifen Beta Scalp Lax-Tab healthE API Airflow m-Captorpril Capoten Ranbaxy-Cefaclor Veracol Aspen Ceftriaxone Cefalexin Sandoz Cefalexin Sandoz PSM Chlorafast Chlorsig healthE Batrafen Zapril

2013 2013 2012 2012 2013 2012 2012 2012 2013 2012 2012 2013 2013 2013 2012 2013 2012 2012 2012 2013

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to September 2011

Generic Name

Cilazapril with hydrochlorothiazide Clobetasol propionate

Presentation

Tab 5 mg with hydrochlorothiazide 12.5 mg Crm 0.05% Oint 0.05% Scalp app 0.05% TDDS 2.5 mg, 100 µg per day TDDS 5 mg, 200 µg per day TDDS 7.5 mg, 300 µg per day Inj 150 µg per ml, 1 ml Tab 25 µg Tab 150 µg Tab 75 mg Vaginal crm 1% with applicator Vaginal crm 2% with applicator Soln BP Tab 500 µg Crm 10% Tab 50 mg Tab 50 mg Tab 50 mg & 100 mg Eye drops 0.1% Inj 4 mg per ml, 1 ml & 2 ml Soln with electrolytes

Brand Name Expiry Date*

Inhibace Plus Dermol Dermol Dermol Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3 Catapres Dixarit Catapres Apo-Clopidogrel Clomazol Clomazol Midwest Colgout Itch-Soothe Nausicalm Cycloblastin Siterone Maxidex Hospira Pedialyte – Fruit Pedialyte – Bubblegum Pedialyte – Plain Diclofenac Sandoz DHC Continus Dilzem Cardizem CD Laxsol Donepezil-Rex Apo-Doxazosin Arrow-Enalapril Clexane Comtan E-Mycin 2013 2012

Clonidine

2012

Clonidine hydrochloride

2012

Clopidogrel Clotrimazole Coal tar Colchicine Crotamiton Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Dexamethasone Dexamethasone sodium phosphate Dextrose with electrolytes

2013 2013 2013 2013 2012 2012 2013 2012 2013 2013 2013

Diclofenac sodium Dihydrocodeine tartrate Diltiazem hydrochloride

Tab EC 25 mg & 50 mg Tab long-acting 60 mg Tab 30 mg & 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab 50 mg with total sennosides 8 mg Tab 5 mg & 10 mg Tab 2 mg & 4 mg Tab 5 mg, 10 mg & 20 mg Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Tab 400 mg

2012 2013 31/12/11

Docusate sodium with sennosides Donepezil hydrochloride Doxazosin mesylate Enalapril Enoxaparin sodium (low molecular weight heparin) Entacapone Erythromycin ethyl succinate

2013 2012 2014 2012 2012 2012 2012

Sole Subsidised Supply Products – cumulative to September 2011

Generic Name

Escitalopram Ethinyloestradiol Etidronate disodium Exemestane Felodipine Fentanyl

Presentation

Tab 10 mg & 20 mg Tab 10 µg Tab 200 mg Tab 25 mg Tab long-acting 5 mg Tab long-acting 10 mg Transdermal patch 12.5 µg per hour, 25 µg per hour, 50 µg per hour, 75 µg per hour, 100 µg per hour Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Eye drops 0.1% Cap 20 mg Tab dispersible 20 mg, scored Tab 250 mg Metered aqueous nasal spray, 50 µg per dose Inj 10 mg per ml, 2 ml Tab 40 mg Crm 2% Oint 2% Cap 100 mg, 300 mg & 400 mg Tab 600 mg Inj 40 mg per ml, 2 ml Liquid Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 50 mg per ml, 1 ml Tab 5 mg & 20 mg Rectal foam 10%, CFC-free (14 applications) Crm 1% with miconazole nitrate 2% Inj 1 mg per ml, 1 ml Tab 200 mg

Brand Name Expiry Date*

Loxalate NZ Medical and Scientific Arrow-Etidronate Aromasin Felo 5 ER Felo 10 ER Mylan Fentanyl Patch Ferodan AFT AFT AFT FML Fluox Fluox Flutamin Flixonase Hayfever & Allergy Frusemide-Claris Diurin 40 Foban Foban Nupentin Lipazil Pfizer healthE Serenace Serenace Serenace Solu-Cortef Douglas Colifoam Micreme H ABM Hydroxocobalamin Plaquenil 2013 2012 2012 2014 2012 2013

Ferrous sulphate Flucloxacillin sodium

2013 2012

Fluorometholone Fluoxetine hydrochloride Flutamide Fluticasone propionate Furosemide Fusidic acid Gabapentin Gemfibrozil Gentamicin sulphate Glycerol Haloperidol

2012 2013 2013 31/1/13 2013 2012 2013 31/7/12 2013 2012 2013 2013

Hydrocortisone Hydrocortisone acetate Hydrocortisone with miconazole Hydroxocobalamin Hydroxychloroquine sulphate

2013 2012 2012 2013 2012 2012

Sole Subsidised Supply Products – cumulative to September 2011

Generic Name

Ibuprofen Indapamide Ipratropium bromide

Presentation

Oral liq 100 mg per 5 ml Tab 2.5 mg Aqueous nasal spray, 0.03%, 15 ml OP Nebuliser soln, 250 µg per ml, 1 ml & 2 ml Tab 20 mg Tab long-acting 40 mg Cap 10 mg & 20 mg Cap 100 mg Oral liq 10 g per 15 ml Oral liq 10 mg per ml Tab 150 mg Eye drops 50 µg per ml Tab 2.5 mg Subdermal implant (2 x 75 mg rods) Inj 1%, 5 ml & 20 ml Crm 2.5% with prilocaine 2.5% (5 g tubes) Crm 2.5% with prilocaine 2.5%; 30 g OP Tab 5 mg, 10 mg & 20 mg Cap 2 mg Oral liq 1 mg per ml Tab 10 mg Tab 1 mg & 2.5 mg Liq 0.5% Shampoo 1% Device Tab 160 mg Tab 50 mg Enema 1 g per 100 ml Tab immediate-release 500 mg & 850 mg Tab 5 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml

Brand Name Expiry Date*

Fenpaed Dapa-Tabs Univent Univent Ismo 20 Corangin Oratane Itrazole Laevolac 3TC 3TC Hysite Letara Jadelle Xylocaine EMLA EMLA Arrow-Lisinopril Diamide Relief Lorapaed Loraclear Hayfever Relief Ativan A-Lices A-Lices Foremount Child’s Silicone Mask Apo-Megestrol Purinethol Pentasa Apotex Methatabs Biodone Biodone Forte Biodone Extra Forte 2012 2013 2013 2014 2012 2013 2013 2013 2012 2012 31/12/13 2013 2013 2013 2013 2013

Isosorbide mononitrate Isotretinoin Itraconazole Lactulose Lamivudine Latanoprost Letrozole Levonorgestrel Lignocaine hydrochloride Lignocaine with prilocaine

Lisinopril Loperamide hydrochloride Loratadine

Lorazepam Malathion Mask for Spacer Device Megestrol acetate Mercaptopurine Mesalazine Metformin hydrochloride Methadone hydrochloride

2013 2013 30/9/11 2012 2013 2012 2012 2013 2012

Sole Subsidised Supply Products – cumulative to September 2011

Generic Name

Methotrexate Methylprednisolone Methylprednisolone sodium succinate

Presentation

Inj 25 mg per ml, 2 ml & 20 ml Tab 2.5 mg & 10 mg Tab 4 mg & 100 mg Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g Tab 10 mg Tab 150 mg & 300 mg Crm 0.1% Oint 0.1% Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg Tab immediate release 10 mg & 20 mg Inj 80 mg per ml, 1.5 ml & 5 ml Dry Tab 250 mg Tab 500 mg Tab 50 mg Oral suspension 10 mg per ml Tab 200 mg

Brand Name Expiry Date*

Hospira Methoblastin Medrol Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Metamide Apo-Moclobemide m-Mometasone m-Mometasone RA-Morph RA-Morph RA-Morph RA-Morph m-Elson Sevredol Hospira Konsyl-D Noflam 250 Noflam 500 Naltraccord Viramune Suspension Viramune Habitrol Habitrol Noriday 28 Nilstat Nilstat Dr Reddy’s Ondansetron Dr Reddy’s Ondansetron Syntocinon Syntocinon Syntometrine Dr Reddy’s Pantoprazole 2013 2012 2012 2012

Metoclopramide hydrochloride Moclobemide Mometasone furoate Morphine hydrochloride

2014 2012 2012 2012

Morphine sulphate

2013 2012 2013 2013 2012 2013 2012

Morphine tartrate Mucilaginous laxatives Naproxen Natrexone hydrochloride Nevirapine

Nicotine Norethisterone Nystatin Ondansetron

Lozenge 1 mg & 2 mg Patch 7 mg, 14 mg & 21 mg Tab 350 µg Cap 500,000 u Tab 500,000 u Tab disp 4 mg & 8 mg Tab 4 mg & 8 mg

2014 2012 2013 2013

Oxytocin

Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Tab 20 mg & 40 mg

2012

Pantoprazole

2013

Sole Subsidised Supply Products – cumulative to September 2011

Generic Name

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Peak Flow Meter Pegylated interferon alpha-2A

Presentation

Eye oint with soft white paraffin Tab 20 mg Low range and Normal range Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Cap potassium salt 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 5 mg, 10 mg & 15 mg Tab 15 mg, 30 mg & 45 mg Tab 500 µg Tab long-acting 600 mg Oral liq 5 mg per ml Cassette Oral liq 5 mg per 5 ml Tab 300 mg Cap 150 mg Tab 0.25 mg, 1 mg, 2 mg & 5 mg Tab 150 mg & 300 mg Oral liq 2 mg per 5 ml Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratopium bromide 0.5 mg per vial, 2.5 ml Tab 5 mg Tab 50 mg & 100 mg Inj 23.4%, 20 ml Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml

Brand Name Expiry Date*

Lacri-Lube Loxamine Breath-Alert Pegasys Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Cilicaine VK AFT AFT Apo-Pindolol Pizaccord Sandomigran Span-K Redipred Innovacon hCG One Step Pregnancy Test Promethazine Winthrop Elixir Q 300 Mycobutin Ropin ArrowRoxithromycin Salapin Asthalin Asthalin Duolin 2012 2012 2012 2012 2012 2012 2012 2012 2013 2013 2012 2013 2012 2012 2013 2013 30/9/11 31/12/12

Phenoxymethylpenicillin (Pencillin V)

2013

Pindolol Pioglitazone Pizotifen Potassium chloride Prednisone sodium phosphate Pregnancy tests – hCG urine Promethazine hydrochloride Quinine sulphate Rifabutin Ropinirole hydrochloride Roxithromycin Salbutamol

Salbutamol with ipratropium bromide Selegiline hydrochloride Sertraline Sodium chloride Sodium citrate with sodium lauryl sulphoacetate

Apo-Selegiline Arrow-Sertraline Biomed Micolette

2012 2013 2013 2013

Sole Subsidised Supply Products – cumulative to September 2011

Generic Name

Sodium citro-tartrate Sodium cromoglycate Somatropin Sotalol Spacer Device Spironolactone Sumatriptan Tamoxifen citrate Tamsulosin hydrochloride Terazosin hydrochloride Testosterone undecanoate Timolol maleate Tranexamic acid Tropisetron Vitamin B complex Vitamins Zidovudine [AZT] September changes in bold

Presentation

Grans effervescent 4 g sachets Eye drops 2% Nasal spray, 4% Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) Tab 80 mg & 160 mg 230 ml, autoclavable & single patient Tab 25 mg & 100 mg Inj 12 mg per ml, 0.5 ml Tab 50 mg & 100 mg Tab 20 mg Cap 400 µg Tab 1 mg, 2 mg & 5 mg Cap 40 mg Tab 10 mg Tab 500 mg Cap 5 mg Tab, strong, BPC Tab (BPC cap strength) Cap 100 mg Oral liq 10 mg per ml

Brand Name Expiry Date*

Ural Rexacrom Rex Genotropin Genotropin Mylan Space Chamber Spirotone Arrow-Sumatriptan Arrow-Sumatriptan Genox Tamsulosin-Rex Arrow Arrow-Testosterone Apo-Timol Cycklokapron Navoban B-PlexADE MultiADE Retrovir Retrovir 2013 2013 2012 31/12/12 2012 30/9/11 2013 2013 2014 2013 2013 2012 2012 2013 2012 2013 2013 2013

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 September 2011

45 PRAVASTATIN – Special Authority see SA0932 – Retail pharmacy See prescribing guideline Tab 20 mg ............................................................................... 5.44 Tab 40 mg ................................................................................ 9.28 CANDESARTAN – Special Authority see SA0933 – Retail pharmacy ❋ Tab 4 mg – No more than 1.5 tab per day ............................... 48.66 ❋ Tab 8 mg – No more than 1.5 tab per day ................................ 57.90 ❋ Tab 16 mg – No more than 1 tab per day ................................. 70.62 ❋ Tab 32 mg – No more than 1 tab per day .............................. 115.50 FINASTERIDE – Special Authority see SA0928 – Retail pharmacy Tab 5 mg ................................................................................. 5.10 LEVOTHYROXINE ❋ Tab 100 µg .............................................................................. 4.21 ‡ Safety cap for extemporaneously compounded oral liquid preparations. TERBINAFINE Tab 250 mg ............................................................................. 1.78 30 30 90 90 90 90 30 90 ✔ Cholvastin ✔ Cholvastin ✔ Candestar ✔ Candestar ✔ Candestar ✔ Candestar ✔ Rex Medical ✔ Synthroid

70 76

✔ Dr Reddy’s Terbinafine

MEFENAMIC ACID – Additional subsidy by Special Authority see SA1038 – Retail pharmacy ❋ Cap 250 mg ............................................................................. 1.25 50 (9.16) Ponstan BICALUTAMIDE – Special Authority see SA0941 – Retail pharmacy Tab 50 mg .............................................................................. 10.00 28 ✔ Bicalaccord

153

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 September 2011

26 BUDESONIDE Cap 3 mg – Special Authority see SA1155 0913 – Retail pharmacy ............................................................. 166.50 90 ✔ Entocort CIR

➽ SA1155 0913 Special Authority for Subsidy Initial application – (Crohn's disease) from any relevant practitioner. Approvals valid for 6 3 months for applications meeting the following criteria: Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn’s disease; and 2 Any of the following: 2.1 Diabetes; or 2.2 Cushingoid habitus; or 2.3 Osteoporosis where there is significant risk of fracture; or 2.4 Severe acne following treatment with conventional corticosteroid therapy; or 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated). Initial application – (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months for patients with diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies. Initial application – (gut graft versus host disease) from any relevant practitioner. Approvals valid for 6 months for patients with gut graft versus host disease following allogenic bone marrow transplantation* Note: Indication marked with * is an Unapproved Indication. Renewal from any relevant practitioner. Approvals valid for 6 3 months where the treatment remains appropriate and the patient is benefiting from treatment. The patient may not have had more than 1 prior approval in the last year. Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate. 81 BENZYLPENICILLIN SODIUM (PENICILLIN G) Inj 1 mega u Inj 600 mg – Up to 5 inj available on a PSO ............................................................................ 11.50

✔ Sandoz

ADALIMUMAB – Special Authority see SA1156 1059 – Retail pharmacy Inj 40 mg per 0.8 ml prefilled pen ....................................... 1,799.92 2 ✔ HumiraPen Inj 40 mg per 0.8 ml prefilled syringe ................................. 1,799.92 2 ✔ Humira ➽ SA1156 1059 Special Authority for Subsidy Initial application - (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from etanercept; or 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or 2 All of the following: 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

continued... 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or and hydroxychloroquine sulphate (at maximum tolerated doses); and 2.5 Either Any of the following: 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate another agent; and 2.6 Either: 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and 2.7 Either: 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (Crohn’s disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following: 1 Patient has severe active Crohn’s disease; and 2 Any of the following: 2.1 Patient has a Crohn’s Disease Activity Index (CDAI) score of greater than or equal to 300; or 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and 4 Surgery (or further surgery) is considered to be clinically inappropriate. Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from etanercept; or 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or 2 All of the following: 2.1 Either: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

continued...

Changes to Restrictions - effective 1 September 2011 (continued)

2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and 2.4 The most recent PASI assessment is no more than 1 month old at the time of application. Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Initial application - (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from etanercept; or 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or 2 All of the following: 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and 2.5 Either: 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober’s test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale. Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application. Average normal chest expansion corrected for age and gender: 18-24 years - Male: 7.0 cm; Female: 5.5 cm 25-34 years - Male: 7.5 cm; Female: 5.5 cm 35-44 years - Male: 6.5 cm; Female: 4.5 cm 45-54 years - Male: 6.0 cm; Female: 5.0 cm 55-64 years - Male: 5.5 cm; Female: 4.0 cm continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

continued... 65-74 years - Male: 4.0 cm; Female: 4.0 cm 75+ years - Male: 3.0 cm; Female: 2.5 cm Initial application - (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from etanercept; or 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or 2 All of the following: 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and 2.4 Either: 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 15 active, swollen, tender joints; or 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and 2.5 Any of the following: 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months. Renewal - (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 3 Either: 3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and 4 Either: 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response. Renewal — (Crohn’s disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

continued... 1 Either: 1.1 Applicant is a gastroenterologist; or 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Either: 2.1 Either: 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or 2.1.2 CDAI score is 150 or less; or 2.2 Both: 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days. Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a dermatologist; or 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Either: 2.1 Both: 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or 2.2 Both: 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and 2.2.2 Either: 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre adalimumab treatment baseline value; and 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days. Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from preadalimumab baseline on a 10 point scale, or by 50%, whichever is less; and 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and continued...

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

continued... 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days. Renewal - (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and 2 Either: 2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or 2.2 The patient demonstrates at least a continuing 50% 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days 102 ETANERCEPT – Special Authority see SA1157 1060 – Retail pharmacy Inj 25 mg .............................................................................. 949.96 Inj 50 mg autoinjector ......................................................... 1,899.92 Inj 50 mg prefilled syringe................................................... 1,899.92 4 4 4 ✔ Enbrel ✔ Enbrel ✔ Enbrel

➽ SA1157 1060 Special Authority for Subsidy Initial application - (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following: 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and 3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose); and or a full trial of serial intra-articular corticosteroid injections; and 5 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-15 mg/m² weekly or at the maximum tolerated dose) in combination with one other disease-modifying agent; and 56 Both: 56.1 Either: 56.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 active, swollen, tender joints; or 56.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and 56.2 Physician's global assessment indicating severe disease. Initial application - (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from adalimumab; or 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

continued... 2 All of the following: 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with at least two of the following (triple therapy): sulphasalazine, prednisone at a dose of at least 7.5 mg per day, azathioprine, intramuscular gold, or and hydroxychloroquine sulphate (at maximum tolerated doses); and 2.5 Either Any of the following: 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with therapy at the maximum tolerated dose of cyclosporin alone or in combination with another agent; or 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate another agent; and 2.6 Either: 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and 2.7 Either: 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months. Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from adalimumab; or 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or 2 All of the following: 2.1 Either: 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and continued...

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

continued... 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and 2.4 The most recent PASI assessment is no more than 1 month old at the time of application. Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. Initial application - (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from adalimumab; or 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or 2 All of the following: 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and 2.5 Either: 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober’s test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale. Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application. Average normal chest expansion corrected for age and gender: 18-24 years - Male: 7.0 cm; Female: 5.5 cm 25-34 years - Male: 7.5 cm; Female: 5.5 cm 35-44 years - Male: 6.5 cm; Female: 4.5 cm 45-54 years - Male: 6.0 cm; Female: 5.0 cm 55-64 years - Male: 5.5 cm; Female: 4.0 cm 65-74 years - Male: 4.0 cm; Female: 4.0 cm 75+ years - Male: 3.0 cm; Female: 2.5 cm Initial application - (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

continued... 1.2 Either: 1.2.1 The patient has experienced intolerable side effects from adalimumab; or 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or 2 All of the following: 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and 2.4 Either: 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 15 active, swollen, tender joints; or 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and 2.5 Any of the following: 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months. Renewal - (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a named specialist or rheumatologist; or 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 3 Either: 3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline. Renewal - (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and 3 Either: 3.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and 4 Etanercept to be administered in doses no greater than 50 mg ever 7 days. continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

continued... Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a dermatologist; or 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and 2 Either: 2.1 Both: 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or 2.2 Both: 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and 2.2.2 Either: 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre treatment baseline value; and 3 Etanercept to be administered at doses no greater than 50 mg every 7 days. Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and 4 Etanercept to be administered at doses no greater than 50 mg every 7 days. Renewal - (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 Either: 1.1 Applicant is a rheumatologist; or 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and 2 Either: 2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or 2.2 The patient demonstrates at least a continuing 50% 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

128 OLANZAPINE Tab 2.5 mg – Special Authority (Zyprexa brand only) see SA0741 below – Retail pharmacy .................................... 2.00 (51.07) Tab 5 mg – Special Authority (Zyprexa brand only) see SA0741 below – Retail pharmacy .................................... 3.85 (101.21) Tab 10 mg – Special Authority (Zyprexa brand only) see SA0741 below – Retail pharmacy .................................... 6.35 (204.49)

✔ Dr Reddy’s Olanzapine ✔ Olanzine Zyprexa ✔ Dr Reddy’s Olanzapine ✔ Olanzine Zyprexa ✔ Dr Reddy’s Olanzapine ✔ Olanzine Zyprexa

➽ SA0741 Special Authority for Subsidy Initial application only from a psychiatrist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following: 1 Patient presents with first episode schizophrenia or related psychoses; or 2 Both: 2.1 Patient suffering from schizophrenia and related psychoses or acute mania in bipolar disorder who is likely to benefit from antipsychotic treatment; and 2.2 Either: 2.2.1 An effective dose of risperidone had been trialled and has been discontinued because of unacceptable side effects; or 2.2.2 An effective dose of risperidone had been trialled and has been discontinued because of inadequate clinical response after 4 weeks; or 3 The patient has suffered from an acute episode of schizophrenia or bipolar mania and has been treated with olanzapine short-acting intra-muscular injection. Renewal only from a psychiatrist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Note: Initial prescriptions to be written by psychiatrists or psychiatric registrars and subsequent prescriptions can be written by General Practitioners. 131 OLANZAPINE Wafer 5 mg – Special Authority see SA0739 – Retail pharmacy ................................................... 6.36 28 (102.19) Zyprexa Zydis Wafer 10 mg – Special Authority see SA0739 – Retail pharmacy ................................................... 8.76 28 (204.37) Zyprexa Zydis ➽ SA0739 Special Authority for Subsidy Initial application only from a psychiatrist. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1 The patient meets the current criteria for standard olanzapine tablets; and 2 The patient is unable to take standard olanzapine tablets, or once stabilized refuses to take olanzapine tablets; or the patient is non-adherent to oral therapy with standard olanzapine tablets; and 3 The patient is under direct supervision for administration of medicine. continued...

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2011 (continued)

continued... Renewal only from a psychiatrist. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is unable to take standard olanzapine tablets, or once stabilized refuses to take olanzapine tablets; and 2 The patient is under direct supervision for administration of medicine. Note: Initial prescriptions to be written by psychiatrists and subsequent prescriptions can be written by psychiatric registrars or General Practitioners. 149 THALIDOMIDE – PCT only – Specialist – Special Authority see SA1124 Only on a controlled drug form Cap 50 mg ........................................................................... 490.00 504.00 Cap 100 mg ...................................................................... 1,008.00

28 28

✔ Thalidomide Pharmion ✔ Thalomid ✔ Thalomid

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 September 2011

28 38 39 42 HYOSCINE N-BUTYLBROMIDE ( subsidy) ❋ Inj 20 mg, 1 ml – Up to 5 inj available on a PSO ......................... 9.57 CALCIUM CARBONATE ( subsidy) ❋ Tab eff 1.75 g (1 g elemental).................................................... 6.21 ZINC SULPHATE ( subsidy) ❋ Cap 137.4 mg (50 mg elemental) ............................................ 11.00 PROTAMINE SULPHATE ( price) ❋ Inj 10 mg per ml, 5 ml ............................................................ 22.40 (95.87) CLOTRIMAZOLE ( subsidy) ❋ Crm 1% ..................................................................................... 0.54 a) Only on a prescription b) Not in combination MICONAZOLE NITRATE ( subsidy) ❋ Crm 2% .................................................................................... 0.46 a) Only on a prescription b) Not in combination 5 30 100 10 Artex 20 g OP ✔ Clomazol ✔ Buscopan ✔ Calsource ✔ Zincaps

15 g OP

✔ Multichem

HYDROCORTISONE ( subsidy) ❋ Crm 1% – Only on a prescription ............................................ 14.00 500 g ✔ Pharmacy Health ❋ Powder – Only in combination ................................................. 44.00 25 g ✔ ABM Up to 5% in a dermatological base (not proprietary Topical Corticosteriod – Plain) with or without other dermatological galenicals. BETAMETHASONE VALERATE WITH FUSIDIC ACID ( price) Crm 0.1% with fusidic acid 2%. ................................................. 3.49 (10.45) a) Maximum of 15 g per prescription b) Only on a prescription 15 g OP Fucicort

TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN – Only on a prescription ( subsidy) ❋ Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium .......................................................... 3.05 500 ml ✔ Pinetarsol 5.82 1,000 ml ✔ Pinetarsol IMIQUIMOD – Special Authority see SA0923 – Retail pharmacy ( subsidy) Crm 5% ................................................................................... 62.00 ERGOMETRINE MALEATE ( subsidy) Inj 500 µg per ml, 1 ml – Up to 5 inj available on a PSO ........... 31.00 NORETHISTERONE ( subsidy) ❋ Tab 5 mg – Up to 30 tab available on a PSO ............................ 26.50 12 5 100 ✔ Aldara ✔ DBL Ergometrine ✔ Primolut N

65 70 76

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 September 2011 (continued)

79 81 MEBENDAZOLE – Only on a prescription ( subsidy) Tab 100 mg ........................................................................... 24.19 AMOXYCILLIN ( subsidy) Inj 250 mg .............................................................................. 12.96 Inj 500 mg ............................................................................. 15.08 Inj 1 g – Up to 5 inj available on a PSO..................................... 21.94 BENZYLPENICILLIN SODIUM (PENICILLIN G) ( subsidy) Inj 600 mg – Up to 5 inj available on a PSO.............................. 11.50 FLUCLOXACILLIN SODIUM ( subsidy) Inj 250 mg .............................................................................. 10.86 Inj 500 mg ............................................................................. 11.32 Inj 1 g – Up to 5 inj available on a PSO..................................... 14.28 PROCAINE PENICILLIN ( subsidy) Inj 1.5 mega u – Up to 5 inj available on a PSO ...................... 123.50 MORPHINE SULPHATE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO ................ 5.51 Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 4.79 Inj 15 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 5.01 Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 5.30 118 PETHIDINE HYDROCHLORIDE ( subsidy) a) Only on a controlled drug form b) No patient co-payment payable Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 5.51 Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO .............. 5.83 127 128 LITHIUM CARBONATE ( subsidy) Cap 250 mg ............................................................................. 9.42 OLANZAPINE ( subsidy) Tab 2.5 mg .............................................................................. 2.00 (51.07) Tab 5 mg .................................................................................. 3.85 (101.21) Tab 10 mg ................................................................................ 6.35 (204.49) 24 10 10 10 10 10 10 10 5 ✔ De-Worm ✔ Ibiamox ✔ Ibiamox ✔ Ibiamox ✔ Sandoz ✔ Flucloxin ✔ Flucloxin ✔ Flucloxin ✔ Cilicaine

81 82

82 117

5 5 5 5

✔ DBL Morphine Sulphate ✔ DBL Morphine Sulphate ✔ DBL Morphine Sulphate ✔ DBL Morphine Sulphate

5 5

✔ DBL Pethidine Hydrochloride ✔ DBL Pethidine Hydrochloride ✔ Douglas

100 28

Zyprexa 28 Zyprexa 28 Zyprexa

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 September 2011 (continued)

131 OLANZAPINE ( subsidy) Wafer 5 mg ............................................................................... 6.36 (102.19) Wafer 10 mg ............................................................................. 8.76 (204.37) TEMAZEPAM ( subsidy) Tab 10 mg ................................................................................ 1.27 ‡ Safety cap for extemporaneously compounded oral liquid preparations. CYCLOPHOSPHAMIDE ( subsidy) Inj 1 g – PCT – Retail pharmacy-Specialist ............................... 26.70 Inj 2 g – PCT only – Specialist ................................................. 56.90 CALCIUM FOLINATE ( subsidy) Tab 15 mg – PCT – Retail pharmacy-Specialist ....................... 82.45 FLUDARABINE PHOSPHATE – PCT only – Specialist ( subsidy) Inj 50 mg for ECP .................................................................. 105.00 CETIRIZINE HYDROCHLORIDE ( subsidy) ❋‡ Oral liq 1 mg per ml ................................................................ 3.52 AMINOPHYLLINE ( subsidy) ❋ Inj 25 mg per ml, 10 ml – Up to 5 inj available on a PSO .......... 53.75 FUSIDIC ACID ( price) Eye drops 1% ............................................................................ 4.50 (11.52) ACETAZOLAMIDE ( subsidy) ❋ Tab 250 mg ........................................................................... 17.03 28 Zyprexa Zydis 28 Zyprexa Zydis 25 ✔ Normison

135

141

1 1 10

✔ Endoxan ✔ Endoxan ✔ DBL Leucovorin Calcium

142

143 159 164 166

50 mg OP ✔ Baxter 200 ml 5 5 g OP Fucithalmic 100 ✔ Diamox ✔ Cetirizine - AFT ✔ DBL Aminophylline

168 180

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1090 – Hospital pharmacy [HP3] ( subsidy) Powder .................................................................................... 5.29 400 g OP ✔ Polycal

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 September 2011

25 4.6 Substitution Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer’s Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, subject to unless either or both of the following circumstances apply: a) the Contractor having received a general Authority to Substitute from the Practitioner in relation to the particular medicine or medicines in general; or there is a clinical reason why substitution should not occur; or b) the Practitioner having indicated their Authority to Substitute on the prescription; or the prescriber has marked the prescription with a statement such as ‘no brand substitution permitted’. c) the Practitioner having given their Authority to Substitute in relation to the particular prescription. Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and sign initial the prescription and inform the patient of the brand change.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 September 2011

59 HYDROCORTISONE ❋ Crm 1% – Only on a prescription ............................................ 14.00 ERGOMETRINE MALEATE Inj 500 µg per ml, 1 ml – Up to 5 inj available on a PSO ........... 31.00 MORPHINE SULPHATE a) Only on a controlled drug form b) No patient co-payment payable Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO ................ 5.51 Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 4.79 Inj 15 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 5.01 Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 5.30 500 g ✔ Pharmacy Health PSM ✔ DBL Ergometrine Mayne

117

5 5 5 5

✔ DBL Morphine Sulphate Mayne ✔ DBL Morphine Sulphate Mayne ✔ DBL Morphine Sulphate Mayne ✔ DBL Morphine Sulphate Mayne

118

PETHIDINE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO .............. 5.51 Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO .............. 5.83

5 5

✔ DBL Pethidine Hydrochloride Mayne ✔ DBL Pethidine Hydrochloride Mayne ✔ DBL Leucovorin Calcium Mayne ✔ DBL Aminophylline Mayne

142

CALCIUM FOLINATE Tab 15 mg – PCT – Retail pharmacy-Specialist ....................... 82.45

164

AMINOPHYLLINE ❋ Inj 25 mg per ml, 10 ml – Up to 5 inj available on a PSO. ......... 53.75

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Sole Subsidised Supply

Effective 1 September 2011

For the list of new Sole Subsidised Supply products effective 1 September 2011 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 14-20.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 September 2011

41 CLOPIDOGREL Tab 75 mg ............................................................................... 5.05 Note – Apo-Clopidogrel tab 75 mg, 90 tablet pack, remains subsidised. DIGOXIN ❋ Tab 62.5 µg – Up to 30 tab available on a PSO .......................... 6.94 Note – Lanoxin PG tab 62.5 µg, 240 tablet pack, remains subsidised. 28 ✔ Apo-Clopidogrel

250

✔ Lanoxin PG

SULPHUR Precipitated – Only in combination ............................................ 6.50 100 g ✔ ABM 1) Only in combination with a dermatological base or proprietary Topical Corticosteroid – Plain, refer, page 171 2) With or without other dermatological galenicals. CLARITHROMYCIN – Maximum of 500 mg per prescription; can be waived by Special Authority see SA1131 Tab 250 mg ............................................................................. 5.53 10 ✔ Klacid Note – Klacid tab 250 mg, 14 tablet pack, remains subsidised. RITONAVIR – Special Authority see SA1025 – Retail pharmacy Cap 100 mg ......................................................................... 121.27 NAPROXEN SODIUM ❋ Tab 275 mg ............................................................................. 5.69 SUMATRIPTAN Inj 12 mg per ml, 0.5 ml – Maximum of 10 inj per prescription ............................................................... 36.00 (80.00) 84 120 ✔ Norvir ✔ Sonaflam

92 97 125

2 OP Imigran ✔ ReVia

139 143

NALTREXONE HYDROCHLORIDE – Special Authority see SA0909 – Retail pharmacy Tab 50 mg ........................................................................... 123.00 30

CLADRIBINE – PCT only – Specialist Inj 2 mg per ml, 5 ml ............................................................ 873.00 1 ✔ Litak S29 Note – Litak inj 2 mg per ml, 5 ml delist has been revoked. Litak will remain subsidised. TAMOXIFEN CITRATE ❋ Tab 20 mg ............................................................................... 5.25 (6.66) IPRATROPIUM BROMIDE Aqueous nasal spray, 0.03% .................................................... 8.06 (12.66) METHYL HYDROXYBENZOATE Powder .................................................................................. 10.00 SODIUM BICARBONATE Powder BP – Only in combination ............................................. 9.80 (11.99) Only in extemporaneously compounded omeprazole suspension. 60 Tamoxifen Sandoz 30 ml OP Apo-Ipravent 25 g 500 g ✔ ABM ✔ ABM Biomed

155

164

177 177

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 March 2012

45 PRAVASTATIN – Special Authority see SA0932 – Retail pharmacy See prescribing guideline Tab 10 mg .............................................................................. 27.46 LEVOTHYROXINE ❋ Tab 100 µg ............................................................................ 46.75 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Note – Synthroid tab 100 µg, 90 tab pack, listed 1 September 2011.

30 1,000

✔ Pravachol ✔ Synthroid

MEFENAMIC ACID – Additional subsidy by Special Authority see SA1038 – Retail pharmacy ❋ Cap 250 mg ............................................................................. 2.50 100 (18.33) Ponstan ALLOPURINOL ❋ Tab 300 mg .............................................................................. 4.03 20.15 100 500 ✔ Apo-Allopurinol S29

S29

112

✔ Apo-Allopurinol S29

S29

113

SELEGILINE HYDROCHLORIDE ❋ Tab 5 mg ................................................................................ 16.06

100

✔ Apo-Selegiline S29

S29

135

MIDAZOLAM Note: Midazolam injection will be funded if prescribed for intranasal administration for use in palliative care. Note that only the Hypnovel brand is currently indicated for intranasal administration. Tab 7.5 mg ............................................................................. 10.38 100 (25.00) Hypnovel ‡ Safety cap for extemporaneously compounded oral liquid preparations CARBOHYDRATE SUPPLEMENT – Special Authority see SA1090 – Hospital pharmacy [HP3] Powder .................................................................................. 36.50 5,000 g ✔ Morrex Maltodextrin 182.50 25,000 g ✔ Morrex Maltodextrin ORAL FEED 1 KCAL/ML – Special Authority see SA1104 – Hospital pharmacy [HP3] Powder (chocolate) .................................................................. 4.22 400 g OP Powder (strawberry) ................................................................. 4.22 400 g OP Powder (vanilla) ....................................................................... 4.22 400 g OP ✔ Ensure ✔ Ensure ✔ Ensure

180

190

191

ORAL FEED 1.5KCAL/ML – Special Authority see SA1104 – Hospital pharmacy [HP3] a) Note - Repeats for Fortisip and Ensure Plus will be fully subsidised where the initial dispensing was before 1 April 2011. b) Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube. The prescription must be endorsed accordingly. Liquid (coffee latte) – Higher subsidy of up to $1.33 per 237 ml with Endorsement ..................................................... 0.85 237 ml OP (1.33) Ensure Plus

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 September 2011

16 17 ACETAZOLAMIDE ( price and addition of HSS) Tab 250 mg – 1% DV Nov-11 to 2014 .................................... 17.03 AMINOPHYLLINE ( price, amended brand name and addition of HSS) Inj 25 mg per ml, 10 ml – 1% DV Nov-11 to 2014 ................... 53.75 AMOXYCILLIN ( price and addition of HSS) Inj 250 mg – 1% DV Nov-11 to 2014 ...................................... 12.96 Inj 500 mg – 1% DV Nov-11 to 2014 ...................................... 15.08 Inj 1 g – 1% DV Nov-11 to 2014 ............................................. 21.94 100 5 Diamox DBL Aminophylline Mayne Ibiamox Ibiamox Ibiamox

10 10 10

BACILLUS CALMETTE-GUERIN (BCG) VACCINE (addition of note) Note: Subsidised only for bladder cancer. Note: Any BCG injection containing equal to or greater than 500 million CFU is considered a DV Pharmaceutical. Inj 2-8 × 100 milliion CFU – 1% DV Jan-11 to 2013 ............ 187.37 1 OncoTICE BENZYLPENICILLIN SODIUM (PENICILLIN G) (amended chemical and presentation descriptions,  price and addition of HSS) Inj 600 mg 1 mega u – 1% DV Nov-11 to 2014 ....................... 11.50 10 Sandoz BICALUTAMIDE Tab 50 mg – 1% DV Nov-11 to 2014 ...................................... 10.00 Note – Bicalox tab 50 mg to be delisted 1 November 2011 BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE Inj 0.25% with 1:400,000 adrenaline, 20 ml – 1% DV Nov-11 to 2014 (new listing) ................................. 135.00 Inj 0.5% with 1:200,000 adrenaline, 20 ml – 1% DV Nov-11 to 2014 ( price and addition of HSS) ........ 115.00 28 Bicalaccord

5 5

Marcain with Adrenaline

Marcain with Adrenaline Note: Marcain with Adrenaline inj 0.25% with 1:400,000 of adrenaline, 10 ml to be delisted 1 November 2011 21 BUPIVACAINE HYDROCHLORIDE WITH FENTANYL ( price and addition of HSS) Inf 0.125% with 2 µg fentanyl per ml, 100 ml bag – 1% DV Nov-11 to 2014 .................................................. 210.00 10 Inf 0.125% with 2 µg fentanyl per ml, 200 ml bag – 1% DV Nov-11 to 2014 .................................................. 210.00 10 Inj 0.125% with 2 μg fentanyl per ml, 15 ml prefilled syringe – 1% DV Nov-11 to 2014 ........................................ 72.00 10 Inj 0.125% with 2 μg fentanyl per ml, 20 ml prefilled syringe – 1% DV Nov-11 to 2014 ........................................ 92.00 10 CALCIUM CARBONATE ( price and addition of HSS) Tab eff 1.75 g (1 g elemental) – 1% DV Nov-11 to 2014............ 6.21 30

Bupafen Bupafen Biomed Biomed Calsource

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 September 2011 (continued)

22 CALCIUM FOLINATE ( price, amended brand name and addition of HSS) Tab 15 mg – 1% DV Nov-11 to 2014 ...................................... 82.45 CANDESARTAN Tab 4 mg ................................................................................ 48.66 Tab 8 mg ............................................................................... 57.90 Tab 16 mg ............................................................................. 70.62 Tab 32 mg ........................................................................... 115.50 CEFOTAXIME Inj 1 g – 1% DV Nov-11 to 2014 ............................................. 15.58 Note: Cefotaxime Sandoz inj 1 g to be delisted 1 November 2011 CETIRIZINE HYDROCHLORIDE ( price and addition of HSS) Oral liq 1 mg per ml – 1% DV Nov-11 to 2014 ........................... 3.52 CLADRIBINE Inj 2 mg per ml, 5 ml ............................................................ 873.00 CLOTRIMAZOLE ( price and addition of HSS) Crm 1% – 1% DV Nov-11 to 2014 ............................................. 0.54 CYCLOPHOSPHAMIDE ( price and addition of HSS) Inj 1 g – 1% DV Nov-11 to 2014 ............................................. 26.70 Inj 2 g – 1% DV Nov-11 to 2014 ............................................. 56.90 10 DBL Leucovorin Calcium Mayne Candestar Candestar Candestar Candestar DBL Cefotaxime

90 90 90 90 10

23 24 25 26

200 ml 1 20 g 1 1

Cetirizine - AFT Litak Clomazol Endoxan Endoxan

DALTEPARIN SODIUM (pack size change) Inj 12,500 iu per 0.5 ml prefilled syringe ............................... 169.00 10 Fragmin Inj 15,000 iu per 0.6 ml prefilled syringe ............................... 210.00 10 Fragmin Inj 18,000 iu per 0.72 ml prefilled syringe ............................. 250.00 10 Fragmin Note – Fragmin inj prefilled syringe 12,500 iu per 0.5 ml, 15,000 iu per 0.6 ml and 18,000 iu per 0.72 ml, 5 inj pack, to be delisted 1 November 2011 EMULSIFYING OINTMENT Oint BP 100 g – 1% DV Nov-11 to 2014 .................................... 1.95 Note: AFT emulsifying oint BP 100 g to be delisted 1 November 2011 100 g Jaychem

ERGOMETRINE MALEATE ( price, amended brand name and addition of HSS) Inj 500 µg per ml, 1 ml – 1% DV Nov-11 to 2014 .................... 31.00 5 FINASTERIDE Tab 5 mg – 1% DV Nov-11 to 2014 ......................................... 5.10 Note – Fintral tab 5 mg to be delisted 1 November 2011 FLUCLOXACILLIN SODIUM ( price and addition of HSS) Inj 250 mg – 1% DV Nov-11 to 2014 ...................................... 10.86 Inj 500 mg – 1% DV Nov-11 to 2014 ...................................... 11.32 Inj 1 g – 1% DV Nov-11 to 2014 ............................................. 14.28

DBL Ergometrine Mayne Rex Medical

10 10 10

Flucloxin Flucloxin Flucloxin

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 September 2011 (continued)

34 36 36 FUSIDIC ACID ( price) Eye drops 1% ......................................................................... 11.52 HYDROCORTISONE ( price and addition of HSS) Powder – 1% DV Nov-11 to 2014 ........................................... 44.00 HYDROCORTISONE ( price, amended brand name and addition of HSS) Crm 1%, 500 g – 1% DV Nov-11 to 2014 ................................ 14.00 Note: DV Limit applies to pack sizes of greater than 100 g. 37 37 42 42 45 46 HYOSCINE N-BUTYLBROMIDE ( price and addition of HSS) Inj 20 mg per ml, 1 ml – 1% DV Nov-11 to 2014 ....................... 9.57 IMIQUIMOD ( price and addition of HSS) Crm 5%, sachet – 1% DV Nov-11 to 2014 ............................... 62.00 LITHIUM CARBONATE Cap 250 mg – 1% DV Nov-11 to 2014 ...................................... 9.42 MEBENDAZOLE ( price and addition of HSS) Tab 100 mg – 1% DV Nov-11 to 2014 .................................... 24.19 MICONAZOLE NITRATE ( price and addition of HSS) Crm 2% – 1% DV Nov-11 to 2014 ............................................. 0.46 MORPHINE SULPHATE ( price, amended brand name and addition of HSS) Inj 5 mg per ml, 1 ml – 1% DV Nov-11 to 2014 ......................... 5.51 Inj 10 mg per ml, 1 ml – 1% DV Nov-11 to 2014 ....................... 4.79 Inj 15 mg per ml, 1 ml – 1% DV Nov-11 to 2014 ....................... 5.01 Inj 30 mg per ml, 1 ml – 1% DV Nov-11 to 2014 ....................... 5.30 5 12 100 24 15 g 5 5 5 5 Buscopan Aldara Douglas De-Worm Multichem DBL Morphine Sulphate Mayne DBL Morphine Sulphate Mayne DBL Morphine Sulphate Mayne DBL Morphine Sulphate Mayne Primolut N Ensure Plus 5g 25 g 500 g Fucithalmic ABM Pharmacy Health PSM

47 49

NORETHISTERONE ( price and addition of HSS) Tab 5 mg – 1% DV Nov-11 to 2014 ........................................ 26.50 ORAL FEED 1.5KCAL/ML Liquid (coffee latte) ................................................................... 1.33 Note: Ensure Plus (coffee latte) to be delisted 1 November 2011

100 237 ml

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 September 2011 (continued)

51 PETHIDINE HYDROCHLORIDE ( price, amended brand name and addition of HSS) Inj 50 mg per ml, 1 ml – 1% DV Nov-11 to 2014 ....................... 5.51 5 Inj 50 mg per ml, 2 ml – 1% DV Nov-11 to 2014 ....................... 5.83 5 DBL Pethidine Hydrochloride Mayne DBL Pethidine Hydrochloride Mayne Cholvastin Cholvastin Cilicaine Provive MCT-LCT 1% Provive MCT-LCT 1% Provive MCT-LCT 1% Pfizer

PRAVASTATIN Tab 20 mg – 1% DV Nov-11 to 2014 ........................................ 5.44 Tab 40 mg – 1% DV Nov-11 to 2014 ........................................ 9.28 PROCAINE PENICILLIN ( price and addition of HSS) Inj 1.5 mega u – 1% DV Nov-11 to 2014 ............................... 123.50 PROPOFOL ( price) Inj 1%, 20 ml ............................................................................ 7.60 Inj 1%, 50 ml ............................................................................ 4.00 Inj 1%, 100 ml .......................................................................... 7.60 SODIUM CHLORIDE ( price and addition of HSS) Soln 0.9% for irrigation, 30 ml – 1% DV Nov-11 to 2014 ......... 19.50

30 30 5 5 1 1 30

52 53

57 58

STANDARD SUPPLEMENT ORAL FEED 1.0KCAL/ML Powder (chocolate) .................................................................. 4.22 400 g Ensure Powder (strawberry) ................................................................. 4.22 400 g Ensure Powder (vanilla) ........................................................................ 4.22 400 g Ensure Note: Ensure powder chocolate, strawberry and vanilla 400 g to be delisted 1 November 2011 TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN ( price and addition of HSS) Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium – 1% DV Nov-11 to 2014 ........................ 3.05 500 ml Pinetarsol 5.82 1,000 ml Pinetarsol TEMAZEPAM ( price and addition of HSS) Tab 10 mg – 1% DV Nov-11 to 2014 ........................................ 1.27 TERBINAFINE Tab 250 mg – 1% DV Nov-11 to 2014 ...................................... 1.78 Note – Apo-Terbinafine tab 250 mg to be delisted 1 November 2011 25 14 Normison Dr Reddy’s Terbinafine

59 59

ZINC SULPHATE ( price and addition of HSS) Cap 137.4 mg (50 mg elemental) – 1% DV Nov-11 to 2014 .... 11.00

100

Zincaps

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 August 2011

17 AMLODIPINE ( price and addition of HSS) Tab 5 mg – 1% DV Oct-11 to 2014 ........................................... 2.65 Tab 10 mg – 1% DV Oct-11 to 2014 ......................................... 4.15 CEFOTAXIME ( price and addition of HSS) Inj 500 mg – 1% DV Oct-11 to 2014 ......................................... 1.90 CEFTAZIDIME ( price and addition of HSS) Inj 500 mg – 1% DV Oct-11 to 2014 ......................................... 2.37 CEFTAZIDIME Inj 1 g – 1% DV Oct-11 to 2014 ................................................ 3.25 Inj 2 g – 1% DV Oct-11 to 2014 ................................................ 6.49 Note: Fortum inj 1 g and 2 g to be delisted 1 October 2011. CLARITHROMYCIN Inj 500 mg – 1% DV Oct-11 to 2014 ....................................... 30.00 DAUNORUBICIN Inj 5 mg per ml, 4 ml .............................................................. 99.00 Note: Daunorubiin inj 5 mg per ml, 4 ml to be delisted 1 October 2011 DIPYRIDAMOLE (addition of HSS) Tab long-acting 150 mg – 1% DV Oct-11 to 2014 .................. 11.52 FACTOR EIGHT INHIBITORS BYPASSING AGENT Inj 500 U ............................................................................ 1,640.00 Inj 1,000 U ......................................................................... 3,280.00 FLUCONAZOLE (amended presentation description and brand name) Powder for oral suspension oral liq 10 mg per ml ................... 34.56 IBUPROFEN Tab long-acting 800 mg – 1% DV Oct-11 to 2014 ..................... 8.12 IRON POLYMALTOSE ( price and addition of HSS) Inj 50 mg per ml, 2 ml – 1% DV Oct-11 to 2014 ...................... 19.90 METRONIDAZOLE Inj 500 mg, 100 ml ................................................................... 2.46 MOMETASONE FUROATE Lotn 0.1% ................................................................................. 4.80 Note: Elocon lotn 0.1% to be delisted 1 August 2011 100 100 1 1 1 1 Apo-Amlodipine Apo-Amlodipine Cefotaxime Sandoz Fortum DBL Ceftazidime DBL Ceftazidime

23 23 23

25 27

1 1

Klacid Mayne

28 31

60 1 1 35 ml 30 5 1 30 ml

Pytazen SR FEIBA FEIBA Diflucan POS Brufen SR Ferrum H Baxter Elocon

32 37 39 45 45

OMEPRAZOLE Cap 10 mg – 1% DV Oct-11 to 2014 ......................................... 2.91 90 Omezol Relief Cap 20 mg – 1% DV Oct-11 to 2014 ......................................... 3.78 90 Omezol Relief Cap 40 mg – 1% DV Oct-11 to 2014 ......................................... 5.57 90 Omezol Relief Note: Dr Reddy’s Omeprazole cap 10 mg, 20 mg and 40 mg to be delisted 1 October 2011

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 August 2011 (continued)

48 ONDANSETRON ( DV limit) Tab disp 4 mg – 5% DV May-11 to 2013 .................................. 1.70 Tab disp 8 mg – 5% DV May-11 to 2013 .................................. 2.00 50 PARACETAMOL WITH CODEINE (brand name change) Tab paracetamol 500 mg with codeine phosphate 8 mg – 1% DV Nov-11 to 2014 ............................................. 2.70 10 10 Dr Reddy’s Ondansetron Dr Reddy’s Ondansetron

100

Paracetamol + Codeine (Relieve) Relieve Advate Advate BeneFIX BeneFIX BeneFIX BeneFIX Rapilysin

RECOMBINANT FACTOR VIII Inj 2,000 IU ........................................................................ 1,900.00 Inj 3,000 IU ........................................................................ 2,850.00 RECOMBINANT FACTOR IX Inj 250 IU ............................................................................. 310.00 Inj 500 IU ............................................................................. 620.00 Inj 1,000 IU ....................................................................... 1,240.00 Inj 2,000 IU ....................................................................... 2,480.00 RETEPLASE Inj 10 iu vial........................................................................ 1,850.00 Note: Rapilysin to be delisted 1 October 2011 RITUXIMAB ( price) Inj 100 mg per 10 ml vial ................................................... 1,075.50 Inj 500 mg per 50 ml vial .................................................... 2,688.30 VENLAFAXINE Tab 37.5 mg ........................................................................... 18.64 Tab 75 mg .............................................................................. 37.27 Tab 150 mg ........................................................................... 45.68

1 1 1 1 1 1 2

2 1 28 28 28

Mabthera Mabthera Arrow-Venlafaxine XR Arrow-Venlafaxine XR Arrow-Venlafaxine XR

Section H changes to Part III

Effective 1 September 2011

67 SPECIAL FOOD SUPPLEMENT Powder 1kcal/ml, 400 g Powder 1kcal/ml, 900 g Ensure Sustagen Hospital Formula Ensure Liquid 1.5kcal/ml, 200 ml Ensure Plus Fortisip Liquid 1.5kcal/ml, 237 ml Ensure Plus Liquid 1.5kcal/ml with fibre, 200 ml Fortisip Multi Fibre For use in community/non-hospitalised patients for 10 days prior to hospitalisation and 30 days following discharge.

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to General Rules

Effective 1 August 2011

8 Exceptional Circumstances policies The purpose of the Exceptional Circumstances policies are to provide: • funding from within the Pharmaceutical Budget Community Exceptional Circumstances budget for medication, to be used in the community, in circumstances where the provision of a funded community medication is appropriate, but funding from the Pharmaceutical Budget is not able to be provided through the Pharmaceutical Schedule (“Community Exceptional Circumstances”); or • an assessment process for the DHB Hospitals to determine whether they can fund medication, to be used in the community, in circumstances where the medication is neither a Community Pharmaceutical nor a Discretionary Community Supply Pharmaceutical and where the patient does not meet the criteria for Community Exceptional Circumstances (“Hospital Exceptional Circumstances”); or • funding from the Pharmaceutical Budget for an assessment process for DHB Hospitals to determine whether they can fund pharmaceuticals for the treatment of cancer in their DHB Hospitals, or in association with Outpatient services provided in their DHB hospitals, in circumstances where the pharmaceutical is not identified as a Pharmaceutical Cancer Treatment (“Cancer Exceptional Circumstances”) in Sections A-H of the Pharmaceutical Schedule. Upon receipt of an application for approval for Community Exceptional Circumstances or Hospital Exceptional Circumstances, the Exceptional Circumstances Panel first decides whether an application will be assessed initially under the Community Exceptional Circumstances criteria or the Hospital Exceptional Circumstances criteria. Cancer Exceptional Circumstances is a separate process.

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to General Rules - effective 1 August 2011 (continued)

10 “Cancer Exceptional Circumstances” means the policies and criteria administered by PHARMAC relating to the ability to fund, from a DHB hospital’s own budget, pharmaceuticals for the treatment of cancer that are not identified as Pharmaceutical Cancer Treatments in Sections A-H of the Pharmaceutical Schedule. “Pharmaceutical Budget” means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances. “Pharmaceutical Cancer Treatment” means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must provide access to fund, from their own budgets, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers. Pharmaceutical Cancer Treatments 8.1 DHBs are obliged to fund provide access to Pharmaceutical Cancer Treatments in accordance with the October September 2001 direction from the Minister of Health. Pharmaceutical Cancer Treatments 8.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 direction from the Minister of Health as to pharmaceuticals and indications for which DHBs must provide funding access. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should: a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984; b) be aware of and comply with their obligations under the Health and Disability Commissioner’s Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Index

Pharmaceuticals and brands A Advate ............................................................... 47 Aldara .......................................................... 34, 44 Acetazolamide ............................................. 36, 42 Adalimumab....................................................... 22 Allopurinol.......................................................... 41 Aminophylline ........................................ 36, 38, 42 Amlodipine......................................................... 46 Amoxycillin .................................................. 35, 42 Apo-Allopurinol S29 ........................................... 41 Apo-Amlodipine ................................................. 46 Apo-Clopidogrel ................................................. 40 Apo-Ipravent ...................................................... 40 Apo-Selegiline S29 ............................................. 41 Arrow-Venlafaxine XR......................................... 47 B Bacillus calmette-guerin (bcg) vaccine ............... 42 BeneFIX ............................................................. 47 Benzylpenicillin sodium (penicillin G) ...... 22, 35, 42 Betamethasone valerate with fusidic acid ............ 34 Bicalaccord .................................................. 21, 42 Bicalutamide ................................................ 21, 42 Brufen SR .......................................................... 46 Budesonide ........................................................ 22 Bupafen ............................................................. 42 Bupivacaine hydrochloride with adrenaline .......... 42 Bupivacaine hydrochloride with fentanyl ............. 42 Buscopan .................................................... 34, 44 C Calcium carbonate ....................................... 34, 42 Calcium folinate ..................................... 36, 38, 43 Calsource .................................................... 34, 42 Candesartan................................................. 21, 43 Candestar .................................................... 21, 43 Carbohydrate supplement............................. 36, 41 Cefotaxime................................................... 43, 46 Cefotaxime Sandoz ............................................ 46 Ceftazidime ........................................................ 46 Cetirizine - AFT............................................. 36, 43 Cetirizine hydrochloride ................................ 36, 43 Cholvastin .................................................... 21, 45 Cilicaine ....................................................... 35, 45 Cladribine..................................................... 40, 43 Clarithromycin.............................................. 40, 46 Clomazol...................................................... 34, 43 Clopidogrel ........................................................ 40 Clotrimazole ................................................. 34, 43 Cyclophosphamide ...................................... 36, 43 D Dalteparin sodium .............................................. 43 Daunorubicin ..................................................... 46 DBL Aminophylline ................................. 36, 38, 42 DBL Cefotaxime ................................................. 43 DBL Ceftazidime................................................. 46 DBL Ergometrine .................................... 34, 38, 43 DBL Leucovorin Calcium ........................ 36, 38, 43 DBL Morphine Sulphate .......................... 35, 38, 44 DBL Pethidine Hydrochloride .................. 35, 38, 45 De-Worm ..................................................... 35, 44 Diamox ........................................................ 36, 42 Diflucan ............................................................. 46 Digoxin .............................................................. 40 Dipyridamole...................................................... 46 Dr Reddy’s Olanzapine ....................................... 32 Dr Reddy’s Ondansetron .................................... 47 Dr Reddy’s Terbinafine ................................. 21, 45 E Elocon ............................................................... 46 Emulsifying ointment .......................................... 43 Enbrel ................................................................ 27 Endoxan....................................................... 36, 43 Ensure ................................................... 41, 45, 47 Ensure Plus............................................ 41, 44, 47 Entocort CIR ...................................................... 22 Ergometrine maleate .............................. 34, 38, 43 Etanercept.......................................................... 27 F Factor eight inhibitors bypassing agent ............... 46 FEIBA................................................................. 46 Ferrum H............................................................ 46 Finasteride ................................................... 21, 43 Flucloxacillin sodium .................................... 35, 43 Flucloxin ...................................................... 35, 43 Fluconazole ........................................................ 46 Fludarabine phosphate ....................................... 36 Fortisip .............................................................. 47 Fortisip Multi Fibre .............................................. 47 Fortum ............................................................... 46 Fragmin ............................................................. 43 Fucicort ............................................................. 34 Fucithalmic .................................................. 36, 44 Fusidic acid.................................................. 36, 44 H Humira............................................................... 22 HumiraPen ......................................................... 22 Hydrocortisone ...................................... 34, 38, 44 Hyoscine N-butylbromide ............................. 34, 44 Hypnovel ........................................................... 41 I Ibuprofen ........................................................... 46 Imiquimod ................................................... 34, 44 Ibiamox........................................................ 35, 42 Imigran .............................................................. 40 Ipratropium bromide ........................................... 40

Index

Pharmaceuticals and brands Iron polymaltose ................................................ 46 K Klacid .......................................................... 40, 46 L Lanoxin PG ........................................................ 40 Levothyroxine .............................................. 21, 41 Litak ............................................................ 40, 43 Lithium carbonate ........................................ 35, 44 M Mabthera ........................................................... 47 Marcain with Adrenaline ..................................... 42 Mebendazole................................................ 35, 44 Mefenamic acid ........................................... 21, 41 Methyl hydroxybenzoate ..................................... 40 Metronidazole .................................................... 46 Miconazole nitrate ........................................ 34, 44 Midazolam ......................................................... 41 Mometasone furoate .......................................... 46 Morphine sulphate.................................. 35, 38, 44 Morrex Maltodextrin ........................................... 41 N Naltrexone hydrochloride .................................... 40 Naproxen sodium ............................................... 40 Norethisterone ............................................. 34, 44 Normison ..................................................... 36, 45 Norvir ................................................................ 40 O Olanzapine ............................................. 32, 35, 36 Olanzine ............................................................. 32 Omeprazole........................................................ 46 Omezol Relief ..................................................... 46 OncoTICE........................................................... 42 Ondansetron ...................................................... 47 Oral feed 1.5kcal/ml ..................................... 41, 44 Oral feed 1 kcal/ml ............................................. 41 P Paracetamol + Codeine (Relieve)....................... 47 Paracetamol with codeine .................................. 47 Pethidine hydrochloride .......................... 35, 38, 45 Pinetarsol..................................................... 34, 45 Polycal............................................................... 36 Ponstan ....................................................... 21, 41 Pravachol........................................................... 41 Pravastatin ............................................. 21, 41, 45 Primolut N.................................................... 34, 44 Procaine penicillin ........................................ 35, 45 Propofol ............................................................. 45 Protamine sulphate ............................................ 34 Provive MCT-LCT 1% ......................................... 45 Pytazen SR ........................................................ 46 R Rapilysin ............................................................ 47 Recombinant factor ix ........................................ 47 Recombinant factor viii....................................... 47 Relieve............................................................... 47 Reteplase ........................................................... 47 ReVia ................................................................. 40 Ritonavir ............................................................ 40 Rituximab .......................................................... 47 S Selegiline hydrochloride ..................................... 41 Sodium bicarbonate ........................................... 40 Sodium chloride ................................................. 45 Sonaflam ........................................................... 40 Special food supplement .................................... 47 Standard supplement oral feed 1.0kcal/ml .......... 45 Sulphur .............................................................. 40 Sumatriptan ....................................................... 40 Sustagen Hospital Formula ................................. 47 Synthroid ..................................................... 21, 41 T Tamoxifen citrate................................................ 40 Tamoxifen Sandoz.............................................. 40 Tar with triethanolamine lauryl sulphate and fluorescein............................ 34, 45 Temazepam ................................................. 36, 45 Terbinafine ................................................... 21, 45 Thalidomide ....................................................... 33 Thalidomide Pharmion........................................ 33 Thalomid............................................................ 33 V Venlafaxine ........................................................ 47 Z Zincaps ........................................................ 34, 45 Zinc sulphate................................................ 34, 45 Zyprexa ........................................................ 32, 35 Zyprexa Zydis ............................................... 32, 36

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 September 2011

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 September 2011 Section H cumulative for August and September 2011 Contents Summary of PHARMAC decisions effective 1 September 2011 …. 3 Legislation changes impact on the Pharmaceutical Schedule … 5…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.